Lates News

According to AI Fast News, Open Source Securities issued a research report on August 20, giving a buy rating to Jiuzhili Pharmaceutical (300181.SZ). The reasons for the rating mainly include: 1) The revenue of Wuling and Bailing series products has steadily increased, and the gross profit margin of most products has improved; 2) Deep cultivation of advantageous areas, innovation, and technological empowerment for growth. (Daily Economic News)